The new psychiatric dignosis: disruptive mood dysregulation disorder

Abstract

The DSM-5, adopted in 2013, presents an updated list of affective disorders, which opens with a fundamentally new psychiatric diagnosis of a disruptive mood dysregulation disorder. Disruptive mood dysregulation disorder is diagnosed in children and adolescents aged 6 to 18 years and is manifested by chronic severe and persistent irritability or anger, as well as outbursts of anger disproportionate to the cause. It is obvious that the condition of a significant part of children and adolescents with a disruptive mood dysregulation disorder before the appearance of this diagnosis was mistakenly regarded as manifestations of bipolar disorder. The criterion of the fundamental difference between disruptive mood dysregulation disorder and bipolar disorder is the absence of manic or hypomanic in the first of them. Disruptive mood dysregulation disorder is characterized by high comorbidity and is often combined with oppositional defiant disorder, conduct disorder and attention deficit with hyperactivity, as well as anxiety. The course and prognostic significance of a disruptive mood dysregulation disorder, as well as the choice of the most effective methods of pharmacological treatment and psychotherapy require numerous further studies.

Keywords

disruptive mood dysregulation disorder / bipolar disorder / oppositional defiant disorder / attention deficit hyperactivity disorder / depression / anxiety / antipsychotics / children and adolescents

References

[1] Black DW, Andreasen NC. Introductory textbook of psychiatry. Sixth edition. Arlington: American Psychiatric Publishing; 2014. 760 p.

[2] Black D.W., Andreasen N.C. introductory textbook of psychiatry. Sixth edition. Arlington: American Psychiatric Publishing; 2014. 760 p.

[3] Copeland WE, Angold A, Costello EJ, Egger H. Prevalence, comorbidity, and correlates of DSM-5 proposed disruptive mood dysregulation disorder. Am J Psychiatry. 2013;170(2):173–179. DOI: 10.1176/appi.ajp.2012.12010132.

[4] Copeland W.E., Angold A., Costello E.J., Egger H. Prevalence, comorbidity, and correlates of DSM-5 proposed disruptive mood dysregulation disorder // Am. J. Psychiatry. 2013. Vol. 170. N. 2. P. 173–179. DOI: 10.1176/appi.ajp.2012.12010132.

[5] Dougherty LR, Smith VC, Bufferd SJ et al. DSM-5 disruptive mood dysregulation disorder: Correlates and predictors in young children. Psychol Med. 2014;44(11):2339–2350. DOI: 10.1017/S0033291713003115.

[6] Dougherty L.R., Smith V.C., Bufferd S.J. et al. DSM-5 disruptive mood dysregulation disorder: Correlates and predictors in young children // Psychol. Med. 2014. Vol. 44. N. 11. P. 2339–2350. DOI: 10.1017/S0033291713003115.

[7] Bruno A, Celebre L, Torre G et al. Focus on disruptive mood dysregulation disorder: A review of the literature. Review Psychiatry Res. 2019;(279):323–330. DOI: 10.1016/j.psychres.2019.05.043.

[8] Bruno A., Celebre L., Torre G. et al. Focus on disruptive mood dysregulation disorder: A review of the literature // Review Psychiatry Res. 2019. N. 279 . P. 323–330. DOI: 10.1016/j.psychres.2019.05.043.

[9] Dougherty LR, Smith VC, Bufferd SJ et al. Disruptive mood dysregulation disorder at the age of 6 years and clinical and functional outcomes 3 years later. Psychol Med. 2016;46(5):1103–1114. DOI: 10.1017/S0033291715002809.

[10] Dougherty L.R., Smith V.C., Bufferd S.J. et al. Disruptive mood dysregulation disorder at the age of 6 years and clinical and functional outcomes 3 years later // Psychol. Med. 2016. Vol. 46. N. 5. P. 1103–1114. DOI: 10.1017/S0033291715002809.

[11] Mayes SD, Waxmonsky JD, Calhoun SL, Bixler EO. Disruptive mood dysregulation disorder symptoms and association with oppositional defiant and other disorders in a general population child sample. J Child Adolesc Psychopharmacol. 2016;26(2):101–106. DOI: 10.1089/cap.2015.0074.

[12] Mayes S.D., Waxmonsky J.D., Calhoun S.L., Bixler E.O. Disruptive mood dysregulation disorder symptoms and association with oppositional defiant and other disorders in a general population child sample // J. Child Adolesc. Psychopharmacol. 2016. Vol. 26. N. 2. P. 101–106. DOI: 10.1089/cap.2015.0074.

[13] Edelsohn GA, Abright AR. Editorial: Safer Use of Antipsychotics in Youth (SUAY): should treatment be guided by symptoms? J Am Acad Child Adolesc Psychiatry. 2022;61(1):34–36. DOI: 10.1016/j.jaac.2021.07.009.

[14] Edelsohn G.A., Abright A.R. Editorial: Safer Use of Antipsychotics in Youth (SUAY): should treatment be guided by symptoms? // J. Am. Acad. Child Adolesc. Psychiatry. 2022. Vol. 61. N. 1. P. 34–36. DOI: 10.1016/j.jaac.2021.07.009.

[15] Findling RL, Zhou X, George P, Chappell PB. Diagnostic trends and prescription patterns in disruptive mood dysregulation disorder and bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2022;61(3):434–445. DOI: 10.1016/j.jaac.2021.05.016.

[16] Findling R.L., Zhou X., George P., Chappell P.B. Diagnostic trends and prescription patterns in disruptive mood dysregulation disorder and bipolar disorder // J. Am. Acad. Child Adolesc. Psychiatry. 2022. Vol. 61. N. 3. P. 434–445. DOI: 10.1016/j.jaac.2021.05.016.

[17] Pan P-Y, Fu A-T, Yeh C-B. Aripiprazole/Methylphenidate combination in children and adolescents with disruptive mood dysregulation disorder and attention-deficit/hyperactivity disorder: An open-label study. J Child Adolesc Psychopharmacol. 2018;28(10):682–689. DOI: 10.1089/cap.2018.0068.

[18] Pan P.-Y., Fu A.-T., Yeh C.-B. Aripiprazole/Methylphenidate combination in children and adolescents with disruptive mood dysregulation disorder and attention-deficit/hyperactivity disorder: An open-label study // J. Child Adolesc. Psychopharmacol. 2018. Vol. 28. N. 10. P. 682–689. DOI: 10.1089/cap.2018.0068.

[19] Waxmonsky JG, Baweja R, Bansal PS, Waschbusch DA. A review of the evidence base for psychosocial interventions for the treatment of emotion dysregulation in children and adolescents. Child Adolesc Psychiatr Clin N Am. 2021;30(3):573–594. DOI: 10.1016/j.chc.2021.04.008.

[20] Waxmonsky J.G., Baweja R., Bansal P.S., Waschbusch D.A. A review of the evidence base for psychosocial interventions for the treatment of emotion dysregulation in children and adolescents // Child Adolesc. Psychiatr. Clin. N. Am. 2021. Vol. 30. N. 3. P. 573–594. DOI: 10.1016/j.chc.2021.04.008.

[21] Haller SP, Stoddard J, Botz-Zapp C et al. A randomized controlled trial of computerized interpretation bias training for disruptive mood dysregulation disorder: A fast-fail study. J Am Acad Child Adolesc Psychiatry. 2022;61(1):37–45. DOI: 10.1016/j.jaac.2021.05.022.

[22] Haller S.P., Stoddard J., Botz-Zapp C. et al. A randomized controlled trial of computerized interpretation bias training for disruptive mood dysregulation disorder: A fast-fail study // J. Am. Acad. Child Adolesc. Psychiatry. 2022. Vol. 61. N. 1. P. 37–45. DOI: 10.1016/j.jaac.2021.05.022.

RIGHTS & PERMISSIONS

Portnova A.A., Sivolap Y.P.